Abstract
We are delighted to announce that Plasmatology has entered an exciting new chapter. Beginning with this issue, the journal will be known as Blood & Plasma, a name that reflects our expanded vision and commitment to advancing research across the full spectrum of blood and plasma science.
The journal first launched in 2008 and became Plasmatology in 2021 following a pharmaceutical sponsorship. Under that title, the focus was on plasma and its clinical applications, highlighting the importance of this vital component. During this period, more than 40 articles and reviews from authors in 22 countries were published, underscoring the international reach and relevance of this emerging research area.
Blood and plasma can, of course, be studied in isolation, and such focused research remains central to the mission of Blood & Plasma. However, they are increasingly recognised as dynamic systems whose interactions are critical to immunity, inflammation, infection, and systemic disease. By considering preclinical, retrospective, prospective, observational, and clinical trial studies, as well as technically sound experimental and computational research, we aim to create a collaborative space for diverse scientific perspectives—one that values both specialised and integrative approaches.
What's New?
Blood & Plasma will continue as a gold open-access journal, publishing high-quality, peer-reviewed research that explores the biology, pathology, and therapeutic potential of blood and plasma in human health and disease. Our expanded scope includes, but is not limited to:
The core biological properties of blood and plasma, including fluid dynamics, protein composition, cellular interactions, and their roles in maintaining homeostasis and responding to physiological stress. Molecular and cellular mechanisms, including iron metabolism and immune modulation, in health and disease. Diagnostic innovations, including biomarkers, liquid biopsies, and advanced histological and imaging methods. Hematology and transfusion medicine, including blood product development and plasma-derived therapies. Interdisciplinary intersections with immunology, oncology, cardiovascular medicine, infectious diseases, and regenerative therapies. Population-level studies, addressing epidemiology, disease burden, and health equity in blood and plasma-related conditions.
Our mission remains clear: to foster research that connects molecular biology, clinical practice, pathology, and public health, and to provide a forum for work that advances both scientific understanding and patient care.
Our Commitment to Authors and Readers
As a gold open-access journal, Blood & Plasma remains dedicated to rigorous peer review, ethical publishing standards, transparent reporting, and global accessibility. We invite researchers from all relevant disciplines to contribute original articles and reviews that reflect the diverse and evolving landscape of blood and plasma science, and we look forward to working with our authors, reviewers, and readers to shape the future of this vital field.
Footnotes
Acknowledgements
M365 Copilot was used to enhance language clarity, and the author has verified the accuracy, validity, and appropriateness of the content.
Declaration of conflicting interest
Author Amy Goundry is an employee of Sage Publications Ltd and is the Managing Editor of Blood & Plasma. The author did not take part in the peer review or decision-making process for this submission and has no further conflicts to declare.